Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Jakavi 15 mg Tablet
Manufacturer/Marketed By : Novartis Healthcare Pvt Ltd
$500.37 $464.01
Jakavi 15 mg Tablet is a targeted therapy belonging to the class of Janus kinase inhibitors, designed to effectively manage intermediate or high-risk Myelofibrosis, a rare bone marrow cancer, and...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
Ruxolitinib 15 mg
Active Pharmaceutical Ingredient
Jakavi 15 mg Tablet
500,37$
464,01$
Jakavi 15 mg Tablet is a targeted therapy belonging to the class of Janus kinase inhibitors, designed to effectively manage intermediate or high-risk Myelofibrosis, a rare bone marrow cancer, and Polycythemia Vera, a condition marked by excessive red blood cell production. By inhibiting specific enzymes, Jakavi helps reduce the overactive cell signaling that contributes to these disorders, promoting better blood cell regulation. Before starting treatment with Jakavi, it is essential to conduct a complete blood cell count to ensure the patient’s safety and monitor their response to the medication. This treatment is not advised for individuals younger than 12 years, as its safety and efficacy in this age group have not been established. Patients should be aware of potential side effects, and regular follow-up with healthcare providers is crucial to optimize therapy. As a reliable option for managing these complex hematological conditions, Jakavi empowers patients to achieve better health outcomes. Always consult with a healthcare professional for personalized advice and to address any concerns regarding treatment with Jakavi.
Active Pharmaceutical Ingredient
Uses
• Jakavi 15 mg tablet is primarily used to manage polycythemia vera, a condition characterized by an overproduction of red blood cells. This medication helps to reduce the high red blood cell count, thereby improving blood flow. By decreasing the viscosity of the blood, Jakavi 15 mg tablet lowers the risk of complications such as blood clots. Patients using this treatment often experience better overall health and fewer related symptoms.
• In patients diagnosed with polycythemia vera, Jakavi 15 mg tablet plays a crucial role in symptom relief. The medication alleviates symptoms associated with the disorder, such as fatigue and headaches, which can be debilitating. By effectively managing these symptoms, Jakavi 15 mg tablet enhances the quality of life for individuals affected by this blood disorder. Regular use helps stabilize blood parameters, allowing patients to engage more fully in their daily activities.
• Jakavi 15 mg tablet is beneficial for individuals who have not responded adequately to other treatments for polycythemia vera. This medication offers an alternative approach for managing the condition, providing hope for those who may have limited options. By targeting the underlying mechanisms of the disorder, Jakavi 15 mg tablet can lead to significant improvements in health outcomes. Healthcare providers may recommend this treatment as part of a comprehensive management plan for their patients.
• The use of Jakavi 15 mg tablet is also associated with a decrease in the risk of thrombotic events in patients with polycythemia vera. Thrombosis can lead to serious complications, and this medication helps mitigate that risk. By promoting healthier blood flow, Jakavi 15 mg tablet supports cardiovascular health. This aspect of treatment is particularly important for patients at higher risk due to their condition.
Benefits
Jakavi 15 mg Tablet can be effective in reducing symptoms associated with myelofibrosis, such as fatigue, enlarged spleen, and uncontrolled bleeding Jakavi 15 mg may improve the overall quality of life and reduce the symptoms of myelofibrosis. Anti-cancer Drug Jakavi has been shown to reduce bone marrow fibrosis (scarring) in those with myelofibrosis. Jakavi 15 mg Strip prevents cancer in those with myelofibrosis and helps to prevent the progression of myelofibrosis to acute myeloid leukemia (AML).
Side Effects
Like all medicines, Jakavi 15 mg may have side effects. If you experience any, contacting your doctor or healthcare provider as soon as possible is important. They may be able to offer strategies to help manage or reduce the severity of these side effects.
Most Common Side Effects
• Headache
• Dizziness
• Weight gain
• High blood pressure
• High cholesterol
• Flatulence
• Abnormal liver function tests
• Difficulty in breathing
• Constipation
Common Side Effects
• Decrease in red blood cells
• Infection
How To Use
You can take Ruxolitinib Tablet 15 mg with or without food. Make sure that you take it at the same time of day every day. Swallow the pill entirely with a drink of water. Do not crush, chew, or open the tablet. If you miss a dose of this medicine, take it as soon as you remember to do so. Skip the missed dose and resume your regular dosing schedule if it's almost time for your next dose. To make up for a missed dose, do not take two doses at once.
Safety Advice
• Alcohol: It's a good idea to avoid drinking alcohol while taking Jakavi 15 mg Tablet. Alcohol may increase the risk of side effects or decrease the effectiveness of Ruxolitinib Tablet 15 mg. For your safety, consult your doctor or pharmacist before mixing alcohol with any medication.
• Kidney: Patients with kidney disease should use Jakavi 15 mg Tablet with caution. It's important for these patients to monitor their kidney function regularly while taking Ruxolitinib Tablet 15 mg and to report any unusual symptoms or changes to their healthcare provider immediately. Dosage adjustments for Jakavi 15 mg may be necessary in individuals with kidney disease.
• Breastfeeding: Breastfeeding while using Jakavi 15 mg Tablet is generally not recommended as Jakavi 15 mg can pass into breast milk and potentially harm your baby. If you're currently breastfeeding and using Ruxolitinib Tablet 15 mg, it's important to consult your doctor. They can discuss the potential risks and benefits with you and help you make the best choice for you and your baby.
• Liver: Patients with liver disease should use Jakavi 15 mg Tablet cautiously. It's important for these people to monitor their liver function regularly while using Jakavi 15 mg and to tell their doctor immediately of any unusual symptoms or changes. The dose of Ruxolitinib Tablet 15 mg may need to be adjusted in people with liver disease.
• Pregnancy: Using Jakavi 15 mg Tablet during pregnancy may be risky as animal studies have shown that it may have adverse effects on the developing foetus. If you are pregnant or planning to become pregnant, it is important to discuss the potential risks and benefits of taking Jakavi 15 mg with your doctor. Your doctor can help you make the best decision for your health and the health of your baby.
• Driving: Using Jakavi 15 mg Tablet may cause dizziness, fatigue, and problems with concentration or coordination, which may affect your ability to drive safely. It's important to follow your doctor's advice and take the necessary precautions, such as not driving or operating heavy machinery, if you experience these side effects from Jakavi 15 mg.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.